DVAX Stock Risk & Deep Value Analysis
Dynavax Technologies Corporation
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
The Bottom Line on DVAX
We analyzed Dynavax Technologies Corporation using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran DVAX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
DVAX Stock Risk Analysis
Overall Risk
Moderate
Financial Risk
Low
Market Risk
Medium
About Dynavax Technologies Corporation (DVAX)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Market Cap Category
small
Market Cap
$1.81B
DVAX Deep Value Analysis
DVAX Red Flags & Warning Signs
- âš
Failure of partner vaccines using CpG 1018 in clinical trials
- âš
Increased competitive pressure or pricing erosion for HEPLISAV-B
- âš
Regulatory setbacks for HEPLISAV-B label expansion or partner products
- âš
Unexpected manufacturing issues or supply chain disruptions
Unlock DVAX Red Flags & Risk Warnings
Create a free account to see the full analysis
DVAX Financial Health Metrics
Market Cap
$1.81B
DVAX Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily driven by the proprietary CpG 1018 adjuvant, which is difficult to replicate and has been validated through multiple partnerships. The 2-dose advantage of HEPLISAV-B also provides a durable, though not insurmountable, competitive edge. Its durability hinges on continued patent protection and the successful advancement of partner programs.
DVAX Competitive Moat Analysis
Sign up to see competitive advantages
DVAX Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated late February 2026)
- •Updates on HEPLISAV-B market share expansion
- •Clinical trial readouts from CpG 1018 partner programs
Medium-Term (6-18 months)
- •Potential new CpG 1018 adjuvant partnership announcements
- •Expansion of HEPLISAV-B into new international markets
- •Progress of Valneva's Chikungunya vaccine (using CpG 1018) towards regulatory approval
Long-Term (18+ months)
- •CpG 1018 becoming the adjuvant of choice for a broad range of next-generation vaccines
- •Sustained global growth and leadership of HEPLISAV-B in the adult Hepatitis B vaccine market
- •Internal pipeline development leveraging CpG 1018
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
DVAX Bull Case: What Could Go Right
- ✓
Acceleration in HEPLISAV-B sales growth beyond current expectations
- ✓
Announcement of new, high-value adjuvant collaborations or expanded use cases for CpG 1018
- ✓
Positive clinical trial data or regulatory approvals for partner vaccines utilizing CpG 1018
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
